Tests an ACE inhibitor in women with early heart failure without symptoms
Tests an ACE inhibitor against no medication in women with asymptomatic heart failure.
Key facts
- Who runs it
- University Hospital Maastricht
- Where
- Maastricht, NetherlandsSee the site
- Trial code
- Registry title
- TREASURE trial
- Status
- Recruiting
- Phase
- Phase 4
- People taking part
- 130 people, planned
- Started
- 26 Mar 2024
- Expected to end
- 1 Sept 2027
- Type of study
- Interventional
- Record updated
- 28 July 2023
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for premenopausal women with early-stage heart failure that causes no symptoms. They must be at least 6 months past their last birth.
- Age
- 18 to 64 years
- Sex
- Women only
- Disease stage
- Heart failure stage-B or diastolic dysfunction, premenopausal, with or without a history of preeclamptic pregnancy
- Earlier treatment
- Cannot already be using antihypertensive medication
Main reasons for not taking part
- Already using antihypertensive medication
- Systolic blood pressure of ≥180 mmHg and/or diastolic blood pressure of ≥110 mmHg
- Diabetes mellitus, kidney failure (GFR<60 ml/min/1.73m2), auto-immune disease and/or liver insufficiency
- Intention to become pregnant within 2 years, or breastfeeding during the trial
- Chronic hypertension before the complicated pregnancy
The registry criteria, word for word
Show all 13 criteriaShow less
Who can take part
- Women, aged 18 years and older
- Heart failure stage-B or diastolic dysfunction
- Premenopausal, with or without a history of preeclamptic pregnancy
- ≥½ and ≤ 30 years after the (first) (complicated) pregnancy
- Last delivery at least 6 months ago
Who cannot take part
- Already using antihypertensive medication
- Women have the intention to pursue pregnancy within 2 years (as ACE inhibitors may be teratogenic)
- Auto-immune disease(s) prior to the (complicated) pregnancy
- Chronic hypertension prior to the complicated pregnancy
- Suffering diabetes mellitus, kidney failure (GFR<60 ml/min/1.73m2), pre-existent auto-immune disease and/or liver insufficiency
- Systolic blood pressure of ≥180 mmHg and/or diastolic blood pressure of ≥110 mmHg
- Breastfeeding during participation
- Women who do not want themselves and/or their general practitioner and specialist(s) to be informed about the test results
Check if you might fit
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 64 years old?
Where in Netherlands
- University Hospital MaastrichtMaastricht, NetherlandsTaking people
About the trial
What the trial wants to find out
The main-objective is to evaluate the effect of an angiotensin-converting-enzyme (ACE) inhibitor compared to care as usual (i.e. no medication) during a two-year open-labeled treatment period in women with asymptomatic heart failure (HF) on reversibility of aberrant cardiac remodeling in asymptomatic HF towards healthy values.
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record
Print a page for my doctorData and sources
- Registry record
- Listed on the EU's official list of trials (CTIS).
- Official title
- Timely recovery after subclinical heart failure
- Plain-language title
- Tests an ACE inhibitor in women with early heart failure without symptomsGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 9 November 2026.
- Fit questions
- Built from 2022-503135-33-00, who can take part
- Record updated
- 28 July 2023